Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimidex Plus Zoladex in Premenopausal HR+ Metastatic Breast Cancer
NCT00186121Phase 2Completed
- Sponsor
- Stanford University
- Start
- Oct 2000
- Primary completion
- May 2013
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of anastrozole, goserelin in breast cancer, sponsored by Stanford University. Started Oct 2000; status: completed.
02
Drugs
anastrozolegoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00186121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00186121.